We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 125

Brexit: Life Sciences implications
  • Bird & Bird
  • European Union, United Kingdom
  • August 23 2016

On 23 June 2016, the UK public voted to leave the EU. Under Article 50 of the Lisbon Treaty, the EU Treaties shall cease to apply to the UK: from the


UK Patents Court judgment in Dr Reddy’s Laboratories v Eli Lilly
  • Bird & Bird
  • United Kingdom
  • December 31 2008

In a judgment handed down in October of this year, the Patents Court (Mr Justice Floyd) upheld EP (UK) 0,454,436 (the “Patent”) which is owned by Eli Lilly and which protects the schizophrenia drug olanzapine


Paedriatric SPC extension: zero or negative term SPCs
  • Bird & Bird
  • European Union, United Kingdom
  • March 11 2009

Zero or negative term SPCs give rise to a unique disunity amongst the granting authorities in the European Member States


Patent decisions on patents for chiral compounds
  • Bird & Bird
  • United Kingdom
  • May 13 2009

A chiral compound is one which has at least one asymmetric carbon centre


Corevalve Inc. v. Edwards Lifesciences AG & Edwards Lifesciences PVT, Inc
  • Bird & Bird
  • United Kingdom
  • March 11 2009

Edwards Lifesciences, the world leader in replacement heart valves, succeeded in upholding the validity of their patent for a transcatheter valve


Generics (UK) Limited v Synaptech Inc
  • Bird & Bird
  • United Kingdom
  • July 17 2009

On 10 May 2009, the High Court handed down its judgment in Generics (UK) Limited v Synaptech Inc, holding that the "first authorisation to place the product on the market in the Community" in Article 13 of the EC Council Regulation 176892 (the "Regulation") referred only to marketing authorisations granted in accordance with Directive 6565EEC


Edwards Lifesciences AG v Cook Biotech Incorporated
  • Bird & Bird
  • United Kingdom
  • July 17 2009

Mr Justice Kitchin handed down a decision only four weeks after the hearing, finding Cook’s patent invalid and not infringed by Edwards’ SAPIEN heart valve


The government official report on patent protection for biotechnological inventions
  • Bird & Bird
  • Sweden
  • May 7 2008

The Directive on the legal protection of biotechnological inventions (9844EC) was implemented in Swedish law in 2004


Court of Appeal explains the limited application of the Biogen principle to product claims and upholds broad product claim protection for a novel enantiomer
  • Bird & Bird
  • United Kingdom
  • May 7 2008

In a judgment given on 10 April 2008 in H. Lundbeck AS v Generics (UK) Limited & Ors, the English Court of Appeal reversed in part the decision of the Patents Court and in so doing upheld broad product claim protection for escitalopram, the () enantiomer of the racemate citalopram, and that is responsible for the SSRI activity of citalopram


Inclusion in the G-Standard of a generic medicine held not to be infringing
  • Bird & Bird
  • Netherlands
  • August 20 2007

In Glaxo Group Ltd v. Pharmachemie B.V., the District Court of The Hague was asked to consider the question whether the inclusion of the generic medicine Ondansetron in the so-called ‘G-Standard’ prior to the expiry of the patent protection (of a second medical use of) this medicine constituted patent infringement